Diabetic kidney disease affects a growing proportion of people with diabetes and remains the leading cause of end-stage renal ...
Dr Mark Kris breaks down the lazertinib-amivantamab data, noting that the combo shows benefit but fails to address key ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback